DSpace logo

Please use this identifier to cite or link to this item: http://142.54.178.187:9060/xmlui/handle/123456789/16433
Full metadata record
DC FieldValueLanguage
dc.contributor.authorANITHA, POSINA-
dc.contributor.authorRAMKANTH, SUNDARAPANDIYAN-
dc.contributor.authorMOHAMED T S SALEEM-
dc.contributor.authorUMASANKARI, KOMMIREDDY-
dc.contributor.authorREDDY, BODDU PRAVEEN-
dc.contributor.authorCHETTY, MADHUSUDHANA-
dc.date.accessioned2023-01-20T07:40:50Z-
dc.date.available2023-01-20T07:40:50Z-
dc.date.issued2011-04-10-
dc.identifier.citationAnitha, P., Ramkanth, S., Saleem, M. T., Umasankari, K., Reddy, B. P., & Chetty, M. (2011). Preparation, in-vitro and in-vivo characterization of transdermal patch containing glibenclamide and atenolol: a combinational approach. Pak. J. Pharm. Sci, 24(2), 155-163.en_US
dc.identifier.issn1011-601X-
dc.identifier.urihttp://142.54.178.187:9060/xmlui/handle/123456789/16433-
dc.description.abstractA novel aspiration in treatment of chronic disease like diabetes associated with other non communicable disease risk factors, such as hypertension is to provide greater therapeutic effect, overcome the side effects by complex therapeutic regimen and to improve patient compliance upon administering combinational transdermal delivery of Glibenclamide (G) and Atenolol (A) which have not been tested literally. Hence, the present study was designed to develop a transdermal patch containing Glibenclamide and Atenolol using blends of different polymeric combinations such as Hydroxy propyl methyl cellulose (HPMC), Poly vinyl pyrolidone (PVP) and Carbopol (CP). The patches were subjected to physicochemical parameters, in-vitro and in-vivo drug release and in-vitro skin permeation studies. Good results were obtained in all the evaluated parameters. The drug release of all formulation follows zero order kinetics by diffusion mechanism of non fickian diffusion type. Invitro transdermal permeation studies by using rat & goat skin and finally in-vivo studies by using rabbits were carried out for the optimized formulation (GA4 HPMC 1%, PVP 0.5%, CP 0.5%). The developed transdermal delivery system containing Glibenclamide & Atenolol might be a milestone in the combinational therapy of diabetes and hypertension.en_US
dc.language.isoenen_US
dc.publisherKarachi: Faculty of Pharmacy & Pharmaceutical Sciences University of Karachien_US
dc.subjectTransdermal patchesen_US
dc.subjectglibenclamideen_US
dc.subjectatenololen_US
dc.subjectdiabetesen_US
dc.subjecthypertensionen_US
dc.titlePREPARATION, IN-VITRO AND IN-VIVO CHARACTERIZATION OF TRANSDERMAL PATCH CONTAINING GLIBENCLAMIDE AND ATENOLOL: A COMBINATIONAL APPROACHen_US
dc.typeArticleen_US
Appears in Collections:Issue 02

Files in This Item:
File Description SizeFormat 
Paper-10.htm143 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.